Literature DB >> 4074623

A comparison of the cardiovascular effects of (+)-sotalol and (+/-)-sotalol following intravenous administration in normal volunteers.

G D Johnston, M B Finch, J A McNeill, R G Shanks.   

Abstract

In a placebo controlled open study in six healthy male volunteers (+)-sotalol in the dose range 0.125 mg kg-1-2.0 mg kg-1 intravenously, was found to have little or no beta-adrenoceptor blocking activity in comparison to the racemic mixture (+/-)-sotalol. The repolarization effects of (+)- and (+/-)-sotalol on the QTc interval however were comparable over the same dose range. The beta-adrenoceptor blocking activity and repolarization effects of sotalol appear to be unrelated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074623      PMCID: PMC1400709          DOI: 10.1111/j.1365-2125.1985.tb05109.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue.

Authors:  H C Strauss; J T Bigger; B F Hoffman
Journal:  Circ Res       Date:  1970-06       Impact factor: 17.367

2.  A random-zero sphygmomanometer.

Authors:  B M Wright; C F Dore
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

Review 3.  Perspectives in adrenergic beta-receptor blockade.

Authors:  J D Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

4.  Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias.

Authors:  M Laakso; P J Pentikäinen; K Pyörälä; P J Neuvonen
Journal:  Eur Heart J       Date:  1981-08       Impact factor: 29.983

5.  Effects of the beta-adrenoceptor-blocking agent Sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. A placebo-controlled, double-blind cross-over study.

Authors:  D Burckhardt; M Pfisterer; A Hoffmann; F Burkart; H Emmenegger; M Jost; P Bolli; F R Buehler
Journal:  Cardiology       Date:  1983       Impact factor: 1.869

6.  Fluorometric high-performance liquid chromatographic determination of sotalol in biological fluids.

Authors:  M A Lefebvre; J Girault; M C Saux; J B Fourtillan
Journal:  J Pharm Sci       Date:  1980-10       Impact factor: 3.534

7.  Acute prolongation of myocardial refractoriness by sotalol.

Authors:  D H Bennett
Journal:  Br Heart J       Date:  1982-06
  7 in total
  6 in total

Review 1.  Polypharmacy. Pharmacokinetic perspectives.

Authors:  P K Honig; L R Cantilena
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 2.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism.

Authors:  C Funck-Brentano; D J Silberstein; D M Roden; A J Wood; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

4.  (+)-sotalol causes significant occupation of beta-adrenoceptors at concentrations that prolong cardiac repolarization.

Authors:  J Reid; G Duker; O Almgren; V Nerme
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

Review 5.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 6.  Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.

Authors:  S V Advani; B N Singh
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.